Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Ji

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|January 4, 2022
The <i>N</i> -Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease InhibitorsYugendar R Alugubelli, Zhi Zachary Geng, Kai S Yang, et al.
European Journal of Medicinal Chemistry|July 15, 2022
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antiviralsYugendar R Alugubelli, Zhi Zachary Geng, Kai S Yang, et al.
ACS Central Science|March 1, 2022
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based AssayWenyue Cao, Chia-Chuan Dean Cho, Zhi Zachary Geng, et al.
European Journal of Medicinal Chemistry|July 2, 2022
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antiviralsYuying Ma, Kai S Yang, Zhi Zachary Geng, et al.
Journal of Medicinal Chemistry|August 10, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Molecular Therapy. Nucleic Acids|November 8, 2022
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variantsQidong Hu, Ying Zhao, Namir Shaabani, et al.
Oncogenesis|June 22, 2023
Antibody-based binding domain fused to TCRγ chain facilitates T cell cytotoxicity for potent anti-tumor responseZhao Chen, Changyou Lin, Hong Pei, et al.
Scientific Reports|September 15, 2022
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodiesXia Cao, Junki Maruyama, Heyue Zhou, et al.
Med (New York, N.Y.)|January 5, 2024
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|January 4, 2022
The <i>N</i> -Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease InhibitorsYugendar R Alugubelli, Zhi Zachary Geng, Kai S Yang, et al.
European Journal of Medicinal Chemistry|July 15, 2022
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antiviralsYugendar R Alugubelli, Zhi Zachary Geng, Kai S Yang, et al.
ACS Central Science|March 1, 2022
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based AssayWenyue Cao, Chia-Chuan Dean Cho, Zhi Zachary Geng, et al.
European Journal of Medicinal Chemistry|July 2, 2022
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antiviralsYuying Ma, Kai S Yang, Zhi Zachary Geng, et al.
Journal of Medicinal Chemistry|August 10, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Molecular Therapy. Nucleic Acids|November 8, 2022
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variantsQidong Hu, Ying Zhao, Namir Shaabani, et al.
Oncogenesis|June 22, 2023
Antibody-based binding domain fused to TCRγ chain facilitates T cell cytotoxicity for potent anti-tumor responseZhao Chen, Changyou Lin, Hong Pei, et al.
Scientific Reports|September 15, 2022
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodiesXia Cao, Junki Maruyama, Heyue Zhou, et al.
Med (New York, N.Y.)|January 5, 2024
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Pageof 3